A formal NDA process has been initiated with Atabay as new discussions begin to take shape around future pharmaceutical and biotechnology development opportunities.
Imperion Biotechnology has entered a formal NDA process with Atabay as new discussions begin to take shape around future-facing pharmaceutical and biotechnology development opportunities.
The process reflects our broader interest in connecting industrial pharmaceutical strength with biological depth, translational validation and advanced development systems.
Details of the programme remain confidential at this stage.